Hospira fourth-qtr 2014 earnings beat expectations

12 February 2015

US drugmaker Hospira (NYSE: HSP), a leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full-year 2014.

For the fourth quarter of 2014, net sales were $1.13 billion, up 3.9% ( and in line with analysts’ expectations), said Hospira, the subject of a $17 billion takeover bid from Pfizer (NYSE: PFE). On a US generally accepted accounting principles (GAAP) basis, fourth-quarter 2014 diluted earnings per share were $0.21 (+5.0%).

Excluding restructuring charges and other items, earnings were $0.53 a share, up 3.9%, well beating the expectations of analysts polled by Thomson Reuters of earnings per share of $0.42.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK